AbbVie (NYSE:ABBV) Shares Up 1.2% – Here’s Why

Posted by Francis Steltz on Jun 14th, 2026

AbbVie Inc. (NYSE:ABBV – Get Free Report)’s stock price shot up 1.2% during mid-day trading on Friday . The stock traded as high as $228.40 and last traded at $227.5420. 4,050,419 shares were traded during trading, a decline of 40% from the average session volume of 6,753,507 shares. The stock had previously closed at $224.77.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ABBV shares. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, June 7th. Guggenheim reiterated a “buy” rating and issued a $249.00 price target on shares of AbbVie in a report on Friday, May 1st. Royal Bank Of Canada started coverage on AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $240.00 price objective on shares of AbbVie in a report on Thursday, April 30th. Finally, Piper Sandler raised their price objective on AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $253.43.

Get Our Latest Stock Report on AbbVie

AbbVie Stock Performance

The firm has a fifty day simple moving average of $211.05 and a 200 day simple moving average of $219.07. The company has a market capitalization of $402.02 billion, a PE ratio of 112.09, a P/E/G ratio of 0.70 and a beta of 0.32.

AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same period last year, the business posted $2.46 EPS. The business’s revenue was up 12.4% compared to the same quarter last year. Research analysts expect that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of AbbVie by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock valued at $41,155,601,000 after acquiring an additional 448,554 shares in the last quarter. Thornburg Investment Management Inc. lifted its holdings in shares of AbbVie by 25.5% during the 3rd quarter. Thornburg Investment Management Inc. now owns 401,760 shares of the company’s stock valued at $93,024,000 after acquiring an additional 81,625 shares in the last quarter. Channing Capital Management LLC lifted its holdings in shares of AbbVie by 10.5% during the 3rd quarter. Channing Capital Management LLC now owns 55,647 shares of the company’s stock valued at $12,885,000 after acquiring an additional 5,302 shares in the last quarter. Procyon Advisors LLC lifted its holdings in shares of AbbVie by 19.9% during the 4th quarter. Procyon Advisors LLC now owns 32,752 shares of the company’s stock valued at $7,484,000 after acquiring an additional 5,427 shares in the last quarter. Finally, Woodley Farra Manion Portfolio Management Inc. lifted its holdings in shares of AbbVie by 358.1% during the 3rd quarter. Woodley Farra Manion Portfolio Management Inc. now owns 14,746 shares of the company’s stock valued at $3,414,000 after acquiring an additional 11,527 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

About AbbVie

(Get Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.